Research programme: IPL12 series - Inflazyme
Alternative Names: IPL 12a85ME; IPL12 series research programme - InflazymeLatest Information Update: 04 Nov 2017
At a glance
- Originator Inflazyme Pharmaceuticals
- Class Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allergic rhinitis; Asthma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Allergic-rhinitis in Canada
- 04 Nov 2017 No recent reports of development identified for preclinical development in Asthma in Canada
- 29 Jun 2005 This programme is still in active development